IS5582A - Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni. - Google Patents

Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni.

Info

Publication number
IS5582A
IS5582A IS5582A IS5582A IS5582A IS 5582 A IS5582 A IS 5582A IS 5582 A IS5582 A IS 5582A IS 5582 A IS5582 A IS 5582A IS 5582 A IS5582 A IS 5582A
Authority
IS
Iceland
Prior art keywords
azahringaminobenzoic
integrin
antagonists
meta
acid compounds
Prior art date
Application number
IS5582A
Other languages
English (en)
Inventor
E. Rogers Thomas
G. Ruminski Peter
Original Assignee
G.D. Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co filed Critical G.D. Searle & Co
Publication of IS5582A publication Critical patent/IS5582A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/14Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS5582A 1998-03-04 2000-08-04 Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni. IS5582A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04
PCT/US1999/003281 WO1999044994A1 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists

Publications (1)

Publication Number Publication Date
IS5582A true IS5582A (is) 2000-08-04

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5582A IS5582A (is) 1998-03-04 2000-08-04 Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni.

Country Status (29)

Country Link
EP (1) EP1060164A1 (is)
JP (1) JP2002505323A (is)
KR (1) KR20010041584A (is)
CN (1) CN1214011C (is)
AP (1) AP1244A (is)
AR (1) AR018139A1 (is)
AU (1) AU753230B2 (is)
BG (1) BG104740A (is)
BR (1) BR9908470A (is)
CA (1) CA2322207A1 (is)
EA (1) EA200000804A1 (is)
EE (1) EE200000506A (is)
GE (1) GEP20033118B (is)
HR (1) HRP20000574A2 (is)
HU (1) HUP0100865A3 (is)
ID (1) ID25591A (is)
IL (1) IL137653A0 (is)
IS (1) IS5582A (is)
MY (1) MY123908A (is)
NO (1) NO315703B1 (is)
NZ (1) NZ506598A (is)
OA (1) OA11530A (is)
PL (1) PL342726A1 (is)
SK (1) SK13002000A3 (is)
TR (1) TR200002542T2 (is)
UA (1) UA71906C2 (is)
WO (1) WO1999044994A1 (is)
YU (1) YU52000A (is)
ZA (1) ZA994406B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
JP2006514050A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のR異性体
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
JP2010520238A (ja) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド 統合された光活性低分子および統合された光活性低分子使用
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
US9856201B2 (en) * 2014-06-04 2018-01-02 Monsanto Technology Llc 3,6-dichlorosalicylic acid compounds and related synthetic processes
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
MX2022014200A (es) 2020-05-14 2022-12-07 Ube Corp Derivado de 1,4,5,6-tetrahidropirimidin-2-amina.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (ja) 2021-11-12 2023-05-19 Ube株式会社 アルポート症候群を治療または予防するための医薬組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2196769C2 (ru) * 1995-08-30 2003-01-20 Джи. Ди. Сирл Энд Ко. Производные аминобензойной кислоты, фармацевтическая композиция

Also Published As

Publication number Publication date
CN1291978A (zh) 2001-04-18
EA200000804A1 (ru) 2001-04-23
AR018139A1 (es) 2001-10-31
NO315703B1 (no) 2003-10-13
BG104740A (en) 2001-02-28
AP2000001893A0 (en) 2000-09-30
EP1060164A1 (en) 2000-12-20
AU3294799A (en) 1999-09-20
TR200002542T2 (tr) 2001-05-21
SK13002000A3 (sk) 2001-07-10
MY123908A (en) 2006-06-30
HRP20000574A2 (en) 2001-08-31
NO20004316L (no) 2000-11-06
OA11530A (en) 2004-05-17
CN1214011C (zh) 2005-08-10
NO20004316D0 (no) 2000-08-30
BR9908470A (pt) 2000-12-05
GEP20033118B (en) 2003-11-25
PL342726A1 (en) 2001-07-02
HUP0100865A3 (en) 2001-11-28
IL137653A0 (en) 2001-10-31
HUP0100865A2 (hu) 2001-08-28
ID25591A (id) 2000-10-19
WO1999044994A1 (en) 1999-09-10
CA2322207A1 (en) 1999-09-10
NZ506598A (en) 2003-07-25
AP1244A (en) 2004-02-04
AU753230B2 (en) 2002-10-10
UA71906C2 (en) 2005-01-17
ZA994406B (en) 2000-02-11
KR20010041584A (ko) 2001-05-25
EE200000506A (et) 2002-04-15
JP2002505323A (ja) 2002-02-19
YU52000A (sh) 2003-02-28

Similar Documents

Publication Publication Date Title
IS5582A (is) Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni.
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
IS5744A (is) Nýjar 3-arýl-própíónsýruafleiður og -hliðstæður
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
PT1140191E (pt) Combinacoes de inibidores de transporte do acido biliar e de derivados do acido nicotinico utilizados no quadro de perturbacoes cardiovasculares
DK1165516T3 (da) Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
EE200100403A (et) Indooli derivaadid ja nende kasutamine MCP-1 antagonistidena
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
DE69904073D1 (de) Oximderivate und ihre verwendung als latente saüre
PT1119557E (pt) Derivados de indeno- nafto- e benzociclohepta-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorecticos
ATE357443T1 (de) Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
NO20013665L (no) Kaliumsalt av (S)-omeprazol
LV12624B (lv) Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
DE69906754D1 (de) Einbringung von rauchmodifizierenden mitteln in rauchartikeln
EE200100131A (et) Süstelahuste parem stabiilsus
NO20003965D0 (no) Nye dihydroksyheksansyre-derivater
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
DE60008807D1 (de) Binaphtol-monophosphorsäurederivate und deren Verwendung
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
IS2607B (is) Afleiður tryptamíns og hliðstæð efnasambönd ásamt lyfjaforskriftum þeirra
DE69908614D1 (de) Herstellung von n-substituierten-hydroxycycloalkylamin-derivaten
DE60022125D1 (de) Tiefstkühlen von Waren
MA25653A1 (fr) Derives d'amides heterocycliques.